Stockscreener 앱 받기
20.30
0.45%
0.09
시간 외 거래:
20.25
-0.05
-0.25%
전일 마감가:
$20.21
열려 있는:
$20.58
하루 거래량:
1.44M
Relative Volume:
0.84
시가총액:
$2.30B
수익:
$6.94M
순이익/손실:
$-212.39M
주가수익비율:
-8.3608
EPS:
-2.428
순현금흐름:
$-200.60M
1주 성능:
-1.55%
1개월 성능:
-8.31%
6개월 성능:
+99.90%
1년 성능:
+192.09%
1일 변동 폭
$20.29
$21.46
1주일 범위
$19.91
$21.46
52주 변동 폭
$5.1501
$27.65
이뮤놈 Stock (IMNM) Company Profile
명칭
Immunome Inc
전화
610-321-3700
주소
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
20.30 | 2.29B | 6.94M | -212.39M | -200.60M | -2.428 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
이뮤놈 Stock (IMNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-12 | 개시 | H.C. Wainwright | Buy |
| 2025-12-01 | 개시 | Truist | Buy |
| 2025-09-22 | 개시 | Goldman | Buy |
| 2025-09-05 | 개시 | Craig Hallum | Buy |
| 2025-04-02 | 개시 | Lake Street | Buy |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-04-30 | 개시 | JP Morgan | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-01-29 | 개시 | Leerink Partners | Outperform |
| 2023-12-19 | 개시 | Wedbush | Outperform |
| 2021-10-29 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
이뮤놈 주식(IMNM)의 최신 뉴스
Director Philip Wagenheim Sells 65,000 Shares of Immunome Inc (I - GuruFocus
Immunome Inc: director Wagenheim sells $1.3m in shares By Investing.com - Investing.com South Africa
Immunome (NASDAQ:IMNM) Director Philip Wagenheim Sells 28,200 Shares - MarketBeat
Philip Wagenheim Sells 36,800 Shares of Immunome (NASDAQ:IMNM) Stock - MarketBeat
Immunome Inc: director Wagenheim sells $1.3m in shares - Investing.com
Immunome Director Sold Shares Worth Over $1.3M - TradingView
Immunome (IMNM) director sells 65,000 shares in open market - Stock Titan
IMNM PE Ratio & Valuation, Is IMNM Overvalued - Intellectia AI
Immunome Inc stock surges on breakthrough oncology data, drawing DACH biotech investor interest - AD HOC NEWS
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Form 144 Immunome Inc. For: 20 March By Investing.com - Investing.com Australia
Smart Money: Is Immunome Inc forming a breakout patternQuarterly Portfolio Review & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Form 144 Immunome Inc. For: 20 March - Investing.com
[144] Immunome Inc. SEC Filing - Stock Titan
Behavioral Patterns of IMNM and Institutional Flows - Stock Traders Daily
HC Wainwright & Co. initiates coverage of Immunome (IMNM) with buy recommendation - MSN
This Sezzle analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN
Stephens & Co. Maintains Immunome (IMNM) Overweight Recommendation - MSN
Immunome Inc Stock (ISIN: US45254C1062) Eyes Upside as Lock-Up Expires Today Amid Short-Term Buy Sig - AD HOC NEWS
Forecast Cut: What is the long term forecast for Immunome Inc stockBond Market & Fast Gain Stock Trading Tips - baoquankhu1.vn
Certain Stock Options of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2026. - marketscreener.com
Certain Common Stock of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2026. - marketscreener.com
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% - AOL.com
Pivotal bioVenture Partners Investment Advisor LLC Invests $5.88 Million in Immunome, Inc. $IMNM - MarketBeat
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing - AOL.com
Loss Report: Is Immunome Inc forming a breakout pattern2026 Risk Factors & Weekly Stock Breakout Alerts - baoquankhu1.vn
Bienaime buys Immunome (IMNM) shares worth $43,670 - Investing.com Nigeria
Insider Buying: Jean Bienaime Acquires Additional Shares of Immu - GuruFocus
Bienaime buys Immunome (IMNM) shares worth $43,670 By Investing.com - Investing.com South Africa
Immunome (NASDAQ:IMNM) Director Acquires $21,550.00 in Stock - MarketBeat
Immunome (IMNM) director buys 2,000 shares in open market - Stock Titan
Craig-Hallum Initiates Coverage of Immunome (IMNM) with Buy Recommendation - MSN
A Look At Immunome (IMNM) Valuation After Narrower 2025 Loss And New US$156 Million Shelf Registration - simplywall.st
Immunome: Upcoming NDA, Valuation, And Investment Case (NASDAQ:IMNM) - Seeking Alpha
Immunome (IMNM) to Release Earnings on Wednesday - MarketBeat
(IMNM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Immunome (NASDAQ:IMNM) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Is Immunome Inc forming a breakout patternJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Immunome (IMNM) - The Globe and Mail
Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative? - finance.yahoo.com
Whale Trades: How do insiders feel about Immunome IncMarket Sentiment Review & Entry and Exit Point Strategies - baoquankhu1.vn
HC Wainwright Brokers Raise Earnings Estimates for Immunome - MarketBeat
Immunome (IMNM) TTM Net Loss Of US$212 Million Reinforces Bearish Profitability Narratives - Sahm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
HC Wainwright Analysts Boost Earnings Estimates for Immunome - MarketBeat
IMNM: Stephens & Co. Lowers Price Target to $30, Maintains Overw - GuruFocus
Immunome (IMNM): Craig-Hallum Raises Price Target to $36.00 and - GuruFocus
Immunome (NASDAQ:IMNM) Price Target Raised to $36.00 - MarketBeat
Stephens Cuts Immunome (NASDAQ:IMNM) Price Target to $30.00 - MarketBeat
Decoding Immunome Inc (IMNM): A Strategic SWOT Insight - GuruFocus
Immunome (IMNM) Reports Wider Losses and Revenue Decline - GuruFocus
이뮤놈 (IMNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):